Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer

Clinical Colorectal Cancer(2020)10.1016/j.clcc.2020.08.003Source: DataRank Database

First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer is a research paper published in Clinical Colorectal Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.30)OA: hybridTopics (44)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (19)

Crystal S. Denlinger ORCID,Namrata Vijayvergia ORCID,Steven J. Cohen,Igor Astaturov,Efrat Dotan ORCID

Live enrichment

PubMed:32972830 OpenAlex:https://openalex.org/W3070916900

National Institutes of Health

Grant: P30 CA006927

National Institutes of Health

Grant: CA176289

FWCI

0.30

Citation Percentile

0.6%

Citation Trend

2021

2022

2024

hybridLicense: cc-by-nc-nd

journalhttp://www.clinical-colorectal-cancer.com/article/S1533002820301079/pdf

HYBRIDhttps://doi.org/10.1016/j.clcc.2020.08.003

publisherhttp://www.clinical-colorectal-cancer.com/article/S1533002820301079/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1533002820301079?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1533002820301079?httpAccept=text/plain

Fields of Study

Colorectal Cancer Treatments and StudiesChemotherapy-induced cardiotoxicity and mitigationPARP inhibition in cancer therapyMedicineAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineColorectal NeoplasmsDrug Administration ScheduleDrug Resistance, NeoplasmHumansMaleMaximum Tolerated DoseMiddle AgedProgression-Free SurvivalQuinacrine

MeSH Terms

CapecitabineProgression-Free SurvivalAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleHumansMaleMiddle AgedQuinacrineColorectal NeoplasmsDrug Resistance, NeoplasmMaximum Tolerated Dose

Keywords

CapecitabineMedicineColorectal cancerRefractory (planetary science)Internal medicineOncologyPhases of clinical researchCancerClinical trialCancer therapyColon cancerAcridineFluoropyrimidineNth Line Treatment

Sustainable Development Goals

SDG 0: Good health and well-being